Changes of autoantibodies and intercellular adhesion molecule-1 in patients with Graves disease after clinical treatment

Objective: To study the changes of autoantibodies and intercellular adhesion molecule-1 (ICAM-1) in patients with Graves disease (GD) after clinical treatment. Methods: A total of 68 patients with GD admitted to our hospital from August 2018 to August 2019 were selected as the research objects. The thyroid peroxidase antibody (TPOAb), thyroid stimulating antibody (TSAb), and antithyroglobulin antibody (TgAb), ICAM-1, insulin-like growth factor 1 (IGF-1), I nterleukin-6 (IL-6), Interleukin 17 (IL-17) before and after treatment were examined. Results: The levels of TSAb, TgAb and TPOAb after treatment were remarkably lower than those before treatment (P<0.001); the levels of ICAM-1, IGF-1, IL-17 and IL-6 after treatment were noticeably lower than those before treatment (P<0.001); the FT3 and FT4 levels of patients after treatment were significantly lower than those before treatment (P<0.001), and the FSH level was significantly higher than that before treatment (P<0.001). Conclusion: Clinical treatment can remarkably reduce the levels of autoantibodies, ICAM-1 and IGF-1 in GD patients, improve thyroid function, and relieve inflammation. The detection of the above indicators can provide guidance for the progression and treatment of GD.

Automated summary

Clinical treatment can significantly reduce the levels of autoantibodies and ICAM-1 in patients with Graves disease, improve thyroid function, and alleviate inflammation. Detection of these indicators can provide guidance for disease progression and treatment.